What question did this study set out to answer?

This research aims to provide an updated overview of recent patents related to monoamine oxidase inhibitors and their therapeutic applications.

February 19, 2026Expert Opinion on Therapeutic Patents5 citations

View Full Paper

Patents involving monoamine oxidase (MAO): a comprehensive update (2022-2025) on its inhibitors and applications

Q: What does this research mean for the field?

Recently patented MAO inhibitors exhibit significant isoform selectivity and therapeutic potential for diseases such as fibromyalgia, CDKL5-deficient disorder, neuropathic pain, and Alzheimer's disease. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

MSMoataz A. Shaldam SCSimone CarradoriUniversity of Chieti-Pescara MBMarwa BalahaKafrelsheikh University

Key Points

This research aims to provide an updated overview of recent patents related to monoamine oxidase inhibitors and their therapeutic applications.
Reviewed patents related to MAO inhibitors from 2022 to 2025.
Analyzed properties such as isoform selectivity and therapeutic potential.
Identified notable properties of newly patented MAO inhibitors.
Highlighted their potential for treating conditions like fibromyalgia and Alzheimer's disease.

Abstract

Recently patented MAO inhibitors show notable properties, including significant isoform selectivity and therapeutic potential toward other diseases, such as fibromyalgia, CDKL5-deficient disorder, neuropathic pain, and Alzheimer's disease.

Perguntar à IA

Bookmark

View Full Paper

Cite This Study

Shaldam et al. (Mon,) studied this question.

synapsesocial.com/papers/6996a8efecb39a600b3f0301 https://doi.org/https://doi.org/10.1080/13543776.2026.2633345

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Perguntar à IA

Bookmark

View Full Paper